Comparative Pharmacology
Head-to-head clinical analysis: AVALIDE versus TELMISARTAN HYDROCHLOROTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AVALIDE versus TELMISARTAN HYDROCHLOROTHIAZIDE.
AVALIDE vs TELMISARTAN; HYDROCHLOROTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Avalide is a combination of an angiotensin II receptor blocker (irbesartan) and a thiazide diuretic (hydrochlorothiazide). Irbesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide increases sodium and water excretion by inhibiting the Na+/Cl- symporter in the distal convoluted tubule.
Telmisartan is an angiotensin II receptor antagonist that selectively blocks the AT1 receptor, inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and water reabsorption.
AVALIDE (irbesartan/hydrochlorothiazide) is available as tablets containing 150/12.5 mg, 300/12.5 mg, or 300/25 mg. The typical starting dose is 150/12.5 mg once daily, titrated to 300/12.5 mg once daily as needed. Maximum dose is 300/25 mg once daily.
Initial dose: 40 mg telmisartan/12.5 mg hydrochlorothiazide orally once daily. Titrate up to 80 mg telmisartan/25 mg hydrochlorothiazide once daily as tolerated.
None Documented
None Documented
Irbesartan: 11-15 h (terminal), HCTZ: 6-15 h (terminal). Clinical context: Steady state reached in 3-5 days; allows once-daily dosing.
Telmisartan: ~24 hours (range 18–24 h), enabling once-daily dosing. Hydrochlorothiazide: 6–15 hours (average ~9 h); prolonged in renal impairment.
Renal: HCTZ ~70% unchanged; Irbesartan ~20% unchanged, remainder as metabolites via biliary (60%) and renal (20%). Combined: Renal ~50%, biliary/fecal ~50%.
Telmisartan: predominantly biliary/fecal (≥97%), renal <1%. Hydrochlorothiazide: predominantly renal (≥95%) as unchanged drug.
Category C
Category D/X
ARB and Thiazide Diuretic Combination
ARB